Author (ref) | Country | Age (years) | N | Age of prescription (years) | No of prescriptions | Adjusted risk estimate | |||
---|---|---|---|---|---|---|---|---|---|
Atopy | Asthma | Hay fever | Eczema | ||||||
NR = not reported. | |||||||||
Farooqi4 | UK | 14–23 | 1934 | <2 | 1+ v 0 | NR | 3.19 | 2.04 | 2.04 |
Alm5 | Sweden | 5–13 | 675 | Ever | 1+ v 0 | 1.24 | NR | NR | NR |
Von Mutius6 | Germany | 5–11 | 6174 | <1 | 1–2 v 0 | 0.96 | 1.64 | 1.12 | 1.26 |
Wickens7 | New Zealand | 5–10 | 456 | Ever | 1+ v 0 | NR | 2.74 | 1.99 | 1.23 |
Droste8 | Belgium | 7–8 | 1206 (675) | <1 | 1+ v 0 | 1.1 | 1.7 | 2.3 | 1.3 |
Illi9 | Germany | 7 | 1314 | Ever | 2+ v 0/1 | “No effect” | 1.08 | NR | NR |
McKeever10 | UK | 0–11 | 29238 | <1 | 5+ v 0 | NR | 1.99 | 1.14 | 1.01 |
This study | UK | 19–46 | 746 | <5 | 1+ v 0 | 1.16 | 1.84 | 1.24 | NR |